JP2008501785A - 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用 - Google Patents

子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用 Download PDF

Info

Publication number
JP2008501785A
JP2008501785A JP2007526712A JP2007526712A JP2008501785A JP 2008501785 A JP2008501785 A JP 2008501785A JP 2007526712 A JP2007526712 A JP 2007526712A JP 2007526712 A JP2007526712 A JP 2007526712A JP 2008501785 A JP2008501785 A JP 2008501785A
Authority
JP
Japan
Prior art keywords
medicament
treatment
butoxyiminomethylcamptothecin
preparation
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007526712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501785A5 (enExample
Inventor
パオロ・カルミナーティ
マルコ・コルシ
クラウディオ・ツァンナ
フランコ・カヴァッリ
ルカ・ジャンニ
クリスティアーナ・セッサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2008501785A publication Critical patent/JP2008501785A/ja
Publication of JP2008501785A5 publication Critical patent/JP2008501785A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007526712A 2004-06-11 2005-06-08 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用 Withdrawn JP2008501785A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000288A ITRM20040288A1 (it) 2004-06-11 2004-06-11 Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
PCT/IT2005/000320 WO2005120643A2 (en) 2004-06-11 2005-06-08 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014165542A Division JP2014231518A (ja) 2004-06-11 2014-08-15 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用

Publications (2)

Publication Number Publication Date
JP2008501785A true JP2008501785A (ja) 2008-01-24
JP2008501785A5 JP2008501785A5 (enExample) 2008-07-17

Family

ID=34979678

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007526712A Withdrawn JP2008501785A (ja) 2004-06-11 2005-06-08 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
JP2014165542A Pending JP2014231518A (ja) 2004-06-11 2014-08-15 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014165542A Pending JP2014231518A (ja) 2004-06-11 2014-08-15 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用

Country Status (23)

Country Link
US (1) US7700613B2 (enExample)
EP (1) EP1773451B1 (enExample)
JP (2) JP2008501785A (enExample)
KR (1) KR101221640B1 (enExample)
CN (2) CN1953784A (enExample)
AR (1) AR049220A1 (enExample)
AT (1) ATE521351T1 (enExample)
AU (1) AU2005251573B2 (enExample)
BR (1) BRPI0511931A (enExample)
CA (1) CA2565213C (enExample)
CY (1) CY1112032T1 (enExample)
DK (1) DK1773451T3 (enExample)
ES (1) ES2372056T3 (enExample)
HK (1) HK1205951A1 (enExample)
HR (1) HRP20110718T1 (enExample)
IT (1) ITRM20040288A1 (enExample)
MX (1) MXPA06014162A (enExample)
PL (1) PL1773451T3 (enExample)
PT (1) PT1773451E (enExample)
RS (1) RS52038B (enExample)
SI (1) SI1773451T1 (enExample)
TW (1) TWI351283B (enExample)
WO (1) WO2005120643A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213385A1 (en) * 2005-08-10 2008-09-04 Oskar Kalb Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043584A2 (en) * 2001-11-20 2003-05-30 University Of Kentucky Research Foundation Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757514B1 (fr) * 1996-12-20 1999-02-12 Sod Conseils Rech Applic Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
DE69635560T2 (de) * 1995-06-21 2006-08-17 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Camptothecinanaloge, Verfahren zur ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
UA57757C2 (uk) * 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
DK1044977T3 (da) 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043584A2 (en) * 2001-11-20 2003-05-30 University Of Kentucky Research Foundation Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins

Also Published As

Publication number Publication date
TWI351283B (en) 2011-11-01
CN1953784A (zh) 2007-04-25
SI1773451T1 (sl) 2012-01-31
ES2372056T3 (es) 2012-01-13
WO2005120643A8 (en) 2006-12-14
BRPI0511931A (pt) 2008-01-22
CA2565213C (en) 2012-08-07
CA2565213A1 (en) 2005-12-22
AU2005251573B2 (en) 2010-04-15
CY1112032T1 (el) 2015-11-04
ITRM20040288A1 (it) 2004-09-11
PT1773451E (pt) 2011-11-02
JP2014231518A (ja) 2014-12-11
AR049220A1 (es) 2006-07-05
WO2005120643A3 (en) 2006-03-30
CN104352496A (zh) 2015-02-18
AU2005251573A1 (en) 2005-12-22
US7700613B2 (en) 2010-04-20
DK1773451T3 (da) 2011-11-28
KR101221640B1 (ko) 2013-01-14
WO2005120643A2 (en) 2005-12-22
MXPA06014162A (es) 2007-03-07
EP1773451A2 (en) 2007-04-18
EP1773451B1 (en) 2011-08-24
US20080020030A1 (en) 2008-01-24
RS52038B (sr) 2012-04-30
HRP20110718T1 (hr) 2011-12-31
KR20070030246A (ko) 2007-03-15
TW200605891A (en) 2006-02-16
ATE521351T1 (de) 2011-09-15
HK1205951A1 (en) 2015-12-31
PL1773451T3 (pl) 2012-01-31

Similar Documents

Publication Publication Date Title
EP3013335B1 (en) Combination therapy for the treatment of cancer comprising eribulin and lenvatinib
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
EP2785349B1 (en) Combination treatment of cancer
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN108738310A (zh) 用于治疗肌营养不良的方法
JP2017522281A (ja) キノリン誘導体による軟部組織肉腫の治療方法と用途、及び軟部組織肉腫治療するための薬用組成物
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
TW201919618A (zh) 用於治療肉瘤的化合物
EP3503923B1 (en) Combination therapies for the treatment of hepatocellular carcinoma
JP2025509772A (ja) ミルダメチニブの非線形投与
TWI468161B (zh) 組合藥劑之醫藥產品、試劑及用途
CN110013478A (zh) 用于抗肿瘤试剂施用的方法
CN103491952A (zh) 用于治疗癌症的新颖联合疗法
JP2024539476A5 (enExample)
EP1713542A2 (en) COMBINATION OF (a) A DNA TOPOISOMERASE INHIBITOR AND (b) AN IAP INHIBITOR
JP2014231518A (ja) 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
WO2022043955A1 (en) Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
JP2003521497A (ja) 癌のための組み合せ治療
HK1104002A (en) Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms
TW202532086A (zh) 治療對卡介苗療法無反應之高風險非肌肉侵襲性膀胱癌之方法
WO2015092123A1 (en) Compositions comprising glycerophosphorylethanolamine
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150311